Company Description
Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia.
Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers.
The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma.
In addition, it develops INSIGHT-003, which is in phase I to treat 1L NSCLC and solid tumors; INSIGHT-005, which is in phase I to treat metastatic urothelial cancer; IMP761, which is in preclinical trial to treat autoimmune disease; and IMP731 and IMP701 which is in clinical development.
Further, the company develops LAG525, which is in phase II clinical trial to treat solid tumors and blood cancer, triple negative breast cancer, and melanoma; and in phase I to treat triple negative breast cancer.
Immutep has collaboration with Merck & Co., Inc., GlaxoSmithKline, EOC Pharma, Novartis, and Laboratory Corporation of America Holdings.
The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017.
The company was incorporated in 1987 and is based in Sydney, Australia.
| Country | Australia |
| Founded | 1987 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Marc Voigt |
Contact Details
Address: Australia Square, Level 32 Sydney, NSW 2000 Australia | |
| Phone | 61 2 8315 7003 |
| Website | immutep.com |
Stock Details
| Ticker Symbol | IMMP |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| CIK Code | 0001692528 |
| CUSIP Number | 45257L108 |
| ISIN Number | US45257L1089 |
Key Executives
| Name | Position |
|---|---|
| Marc Voigt | Chief Executive Officer, MD, Chief Financial Officer, Chief Business Officer and Executive Director |
| Deanne Miller LLB | Chief Operating Officer, General Counsel and Joint Company Secretary |
| Dr. Frederic Triebel M.D., Ph.D. | Chief Scientific Officer and Executive Director |
| Christian Mueller BBA, MSc. | Chief Development Officer |
| Stephan Winckels M.D., Ph.D. | Acting Chief Medical Officer |
| Indira Naidu | Joint Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 21, 2020 | F-6EF | Registration of American Depository Receipt shares, immediately effective |
| Oct 25, 2019 | 424B3 | Prospectus |
| Feb 13, 2019 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 28, 2018 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Dec 4, 2017 | 424B3 | Prospectus |
| Dec 20, 2016 | 424B3 | Prospectus |